Skip to content

Short-term and long-term outcomes of robotic and laparoscopic major hepatectomy for hepatocellular carcinoma: a prospective randomized controlled trial

Short-term and long-term outcomes of robotic and laparoscopic major hepatectomy for hepatocellular carcinoma: a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023660
Enrollment
Unknown
Registered
2019-06-05
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Group 1:robotic major hepatectomy
Group 2:laparoscopic major hepatectomy

Sponsors

The General Hospital of the People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Preoperative diagnosis of hepatocellular carcinoma is clear and consistent with the postoperative pathology report; (2) The patient's general condition and function of important organs are good enough to tolerate general anesthesia and liver resection; (3) Preoperative enhanced CT, contrast-enhanced ultrasonography or MRI of the upper abdomen are performed and the extent of the resection are more than three liver segments after discussion; (4) Child-Pugh grade A or B of liver function, without any active hepatitis or severe portal hypertension; (5) Reserved liver volume / standard remnant volume = 30%; (6) Complete clinical data; (7) The patient agrees to sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) With active hepatitis or severe portal hypertension; (2) Severe epigastric adhesion caused by previous abdominal surgery results that endoscopic surgical instruments cannot be implanted or CO2 pneumoperitoneum cannot be established; (3) Intraoperative exploration reveals tumor rupture or bloody peritoneal effusion; (4) Preoperative treatment of TACE, RF, radiotherapy or chemotherapy.

Design outcomes

Primary

MeasureTime frame
Overall survival;Disease free survival;90-day mortality rate;Clavien-Dindo grade;Pathological margin;Hospital stay;Time of first feeding after operation;Cost;

Countries

China

Contacts

Public ContactHuang Fei

The General Hospital of the People's Liberation Army

306322689@qq.com+86 18622020293

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026